206
Views
8
CrossRef citations to date
0
Altmetric
Drug Evaluations

Abagovomab for ovarian cancer

, , MD, , MD, , MD, , MD, , MD & show all
Pages 395-403 | Published online: 18 Jan 2011

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Umberto Leone Roberti Maggiore, Filippo Bellati, Ilary Ruscito, Maria Luisa Gasparri, Franco Alessandri, Pier Luigi Venturini & Simone Ferrero. (2013) Monoclonal antibodies therapies for ovarian cancer. Expert Opinion on Biological Therapy 13:5, pages 739-764.
Read now
Suzanne R. Thibodeaux & Tyler J. Curiel. (2011) Immune Therapy for Ovarian Cancer: Promise and Pitfalls. International Reviews of Immunology 30:2-3, pages 102-119.
Read now

Articles from other publishers (6)

Ying Wang, Xia Luo, Nayiyuan Wu, Qianjin Liao & Jing Wang. (2023) SRC-3/TRAF4 facilitates ovarian cancer development by activating the PI3K/AKT signaling pathway. Medical Oncology 40:2.
Crossref
Zhiquan Liang, Ziwen Lu, Yafei Zhang, Dongsheng Shang, Ruyan Li, Lanlan Liu, Zhicong Zhao, Peishan Zhang, Qiong Lin, Chunlai Feng, Yibang Zhang, Peng Liu, Zhigang Tu & Hanqing Liu. (2019) Targeting Membrane Receptors of Ovarian Cancer Cells for Therapy. Current Cancer Drug Targets 19:6, pages 449-467.
Crossref
Marcus Vetter & Viola Heinzelmann-Schwarz. 2017. Immunotherapy - Myths, Reality, Ideas, Future. Immunotherapy - Myths, Reality, Ideas, Future.
Justin M. Drerup, Yang Liu, Alvaro S. Padron, Kruthi Murthy, Vincent Hurez, Bin Zhang & Tyler J. Curiel. (2015) Immunotherapy for Ovarian Cancer. Current Treatment Options in Oncology 16:1.
Crossref
Mildred Felder, Arvinder Kapur, Jesus Gonzalez-Bosquet, Sachi Horibata, Joseph Heintz, Ralph Albrecht, Lucas Fass, Justanjyot Kaur, Kevin Hu, Hadi Shojaei, Rebecca J Whelan & Manish S Patankar. (2014) MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Molecular Cancer 13:1.
Crossref
Alejandro López-Requena, Oscar R. Burrone & Rolando Pérez. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies 407 434 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.